United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccine stocks Pfizer and BioNTech dipped Wednesday after test results in the blood of vaccinated people showed their vaccine could protect humans against the U.K. variant of Covid-19. The post Pfizer Says Covid Jab Could Battle U.K. Variant; Gritstone Expands Its Gain appeared first on Investor's Business Daily.

Pfizer Says Covid Jab Could Battle U.K. Variant; Gritstone Expands Its Gain

American Electric Power Company

Cisco Systems

Con Ed

IDACORP

Lockheed Martin

Merck

Pinnacle West Capital

AT&T

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of dividend growth stocks in Dividend Radar and present the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For January 2021

BioNTech SE

The Covid vaccine developed by Pfizer-BioNTech is likely to be effective against a mutant strain of the virus that was first discovered in the U.K.

Pfizer-BioNTech vaccine found to be effective against Covid variant discovered in the UK

Archer-Daniels-Midland Company

Aflac

Bank of America

Corteva Inc

Chevron

Dominion Energy

DuPont de Nemours

Discover

Dow Inc

Emerson Electric

FirstEnergy

iShares Core S&P Total U.S. Stock Market ETF

Johnson & Johnson

Kraft Heinz

Kroger

McDonald's

Norfolk Southern

J. M. Smucker

Scotts Miracle-Gro

In December, we received $4,699.20 in dividend income. That is a 23.4% increase compared to last year. We received $3,500 from our retirement accounts this month alone. In total, our dividend income increased nearly $10 from dividend increases.

Dividend Income Summary: Bert's December 2020 Summary - New Record

New York Governor Andrew Cuomo asked Pfizer Inc (NYSE: PFE) to sell its COVID-19 vaccine directly to New York in a letter on Monday. What Happened: The governor wrote to the New York-based pharmaceutical giant's CEO Albert Bourla as Pfizer is not bound by supply commitments that rival Moderna Inc (NASDAQ: MRNA) has made under Operation Warp Speed — the federal government's vaccine initiative.

Cuomo Asks Pfizer To Let New York Purchase COVID-19 Vaccine Directly

New York Gov. Andrew Cuomo called on pharmaceutical company Pfizer to sell doses of its coronavirus vaccine directly to New York state, in the hopes of accelerating a process that has languished in recent weeks. The request would require Pfizer to circumvent the federal government's Operation Warp Speed — a campaign to produce and distribute some 300 million doses to Americans in an effort to end the pandemic — and deal directly with Cuomo's state administration.

Cuomo asked Pfizer to sell its COVID-19 vaccine directly to New York, just as the head of the WHO warns of mounting inequities in vaccine distribution

The request comes after an alarmingly slow start to the national vaccine rollout, with the country millions of injections short of initial projections.

New York Gov. Cuomo asks to buy Covid vaccine directly from Pfizer amid dose shortages

Moderna

Two mRNA COVID vaccines aced clinical trials. Now new virus variants are putting them to the test.

Can the Pfizer and Moderna Vaccines Beat the New Coronavirus Strains?

Novavax

Each has more to offer than just a COVID-19 vaccine.

3 Fantastic Coronavirus Vaccine Stocks to Buy Right Now

Pfizer stock has a lot to offer, including a nifty dividend and focus on the future that give confidence to many conservative investors. The post Why Pfizer Is a Long-Term Investor's Friend appeared first on InvestorPlace.

Why Pfizer Is a Long-Term Investor's Friend

U.S. stock market indexes Friday morning were trading at or near sessions lows after a report indicated some delays in the distribution of vaccines from Pfizer in Europe. AFP reported that the European Union's Pfizer vaccine deliveries could be delayed 'for next 3-4 weeks.

Dow skids to session low Friday morning amid report that Pfizer vaccines in EU may face delays

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

Pfizer will temporarily reduce the number of doses of its coronavirus vaccine being delivered to Europe, according to the Norwegian Institute of Public Health.

Pfizer to temporarily reduce Covid vaccine deliveries to Europe

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The safety and efficacy of XALKORI have not been established in older adults with relapsed or re

Pfizer's XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults

American States Water

Clorox

DTE Energy

Enbridge

Home Depot

Altria

Visa

Energy Select Sector SPDR Fund

Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.

A Dividend Investor's Guide To 2021: The Cure To Uncertain Times

AbbVie

Bristol-Myers

Elanco Animal Health Inc

Jazz Pharmaceuticals

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

7 Pharmaceutical Stocks With Exciting Plans for 2021

Pfizer stock fell Tuesday after CEO Albert Bourla offered a 2021 earnings outlook that lagged some expectations. The company now expects to deliver 2 billion Covid vaccine doses in 2021.

Pfizer Skids To 200-Day Line On Earnings Outlook That Lagged Some Views

Pfizer Inc. (PFE) CEO Albert Bourla Presents at 39th Annual JPMorgan Healthcare Conference (Transcript)

News for Pfizer Stock (PFE)